Actively Recruiting
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Led by Institut Bergonié · Updated on 2025-10-02
180
Participants Needed
1
Research Sites
573 weeks
Total Duration
On this page
Sponsors
I
Institut Bergonié
Lead Sponsor
F
Fondation Bergonié
Collaborating Sponsor
AI-Summary
What this Trial Is About
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.
CONDITIONS
Official Title
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Women or men
- Histologically confirmed invasive breast cancer at diagnosis
- Locally advanced inoperable tumors: cT4a, b, c, d or cN2 or cN3
- Operable tumors including cT2cN1, cT3cN0, cT3N1, or cT2cN0 with confirmed lymph node invasion
- No clinically or radiologically detectable metastases before neoadjuvant chemotherapy
- Unilateral or bilateral breast cancer; multifocal tumors allowed
- Received 6 to 8 cycles of neoadjuvant chemotherapy
- Preoperative radiation therapy is allowed
- Breast surgery performed with pathology report showing non-complete histological response
- Signed informed consent
- Affiliated to French social security according to French law
- May be included in another interventional research study
You will not qualify if you...
- cT2cN0 tumor without confirmed lymph node involvement
- Cancer progression during neoadjuvant chemotherapy
- Received only neoadjuvant hormone therapy
- Complete blood transfusion within 120 days before first sample collection
- History of invasive cancer including contralateral invasive breast cancer (except in situ breast cancer, basocellular skin cancer, or cervical cancer treated in situ)
- Unable to comply with study procedures due to geographic, social, or psychological reasons
- Subject to legal protection measures or deprived of liberty
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Bergonie
Bordeaux, France, 33076
Actively Recruiting
Research Team
H
Hervé BONNEFOI, MD, PhD
CONTACT
S
Simone MATHOULIN-PELISSIER, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here